Coronary artery disease (CAD) is a leading cause of disability and death in Canada. Bypass surgery and procedures using balloons and stents to open up blocked vessels are two widely used treatment options for patients with multivessel CAD, and have been shown to improve patient outcomes compared to therapy with medications alone. Clinical practice guidelines have recommended surgery for managing multi-vessel disease in most cases, but increasingly suggest a shared-decision making approach. This is because there is substantial uncertainty about the best treatment approach for stable multivessel disease for many patients, especially in the elder and those living with multimorbidity, which are associated with higher procedural complication risks. Consequently, treatment decisions for these patients with CAD are usually based on Heart Team discussions, which involve discussions among clinical experts about the trade-offs in outcomes associated with different treatment strategies, variability in levels of accepted risk by patients, and institutional clinical practice cultures. These Heart Team discussions are intended to arrive at the best decision for each patient, but explicit risk information is rarely provided to patients nor are patient preferences formally incorporated within the current decision-making process. There is a limited understanding of patients’ preferences towards the different treatment options for patients with stable multivessel disease and how patients' preferences influence shared decision- making for disease management. This study will elicit patient preferences towards these treatment options and develop personalized approaches to communicate the benefit and risk associated with each treatment option to patients. The knowledge gained through this research will be used to support processes and practices for shared decision-making between patients and Heart Teams and ensure delivery of the right treatment to the right patient at the right time.

We want to hear from you about how your university can support your mental health. You will be asked to: Complete a brief online survey and an individual diagnostic interview.

A clinical research study to evaluating the safety and effectiveness of an investigational drug (Mitapivat) in study participants with Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

A registry is a research tool that collects information of the health of individuals with a particular disease over time. This information is then used to improve resources available and quality of care for patients. The Canadian HAE Registry is a Canada-wide registry that captures information from people diagnosed with HAE. Information is then used in a variety of ways to improve HAE care. HOW IT WORKS? Patient-reported information on medical history, treatments and surgeries, attacks, and quality of life is collected from patients. In clinic: Medical information is collected in specialty medical clinics attended by HAE patients. Access to collected information is strictly controlled through an approval process to protect patient privacy. Common uses of registry data include: - notifying patients of clinical trials and other research opportunities - Understanding care patients are receiving and how well it aligns with practice guidelines - advocacy efforts for patient organizations and clinical experts - research to understand the quality of life and impacts on patients and families - research to better understand HAE - clinical research for new therapy development

This is a double-blind, placebo-controlled study, comparing the investigational drug VE303 to placebo. The purpose of RESTORATiVE303 is to see if the investigational drug, VE303, is safe and effective in preventing participants from having another episode of Clostridioides difficile infection (CDI). VE303 is an investigational drug that has 8 strains of live bacteria. These bacteria were selected for inclusion in VE303 because they rarely infect humans (mostly in very weakened patients), they do not carry any toxins that can make you sick, and they are not known to carry any risk of creating or spreading resistance to antibiotics. Participants will be randomly assigned to 1 of 2 treatment groups (subject will be entered into the treatment group by chance -like flipping a coin). Subjects have two-out-of-three chance of getting VE303 as treatment. Double-blind means that the Study Doctor, study staff, the study Sponsor, and the participant will not know whether subject is receiving VE303 or placebo. However, in case of an emergency, the Study Doctor or study staff can find out what study drug subjects are taking. Participation in the study will last approximately 6.5 months. The study begins with a screening period of 10 to 28 days, while participant is taking antibiotics to control the infection. After that, subjects will receive the first dose of study drug. The study includes a total of 7 planned clinic visits and 4 telemedicine visits.

This study will evaluate the safety and effectiveness of an oral medication called deucravacitinib as a therapeutic option for the treatment of patients with active systemic lupus erythematosus (SLE). Study participants could receive either the study medication or placebo for the 52 week treatment period of the study.

The goal of this registry is collect information to help us improve the care and treatment of patients living with systemic lupus erythematosus (SLE). This information will help health researchers to learn more about the short and long term effects of lupus and its treatments on our patient population. Participants will be asked come for a study visit once a year to complete a medical history and quality of life questionnaire. Each study visit will take approximately 30 minutes at the Richmond Road Rheumatology clinic. Once in the registry, participants will be notified of opportunities to participate in other research studies.

Getting readmitted to the hospital after discharge is a common issue in Canada. Canada has some of the lowest numbers of hospital beds per person compared to other countries with universal healthcare. In 2020-2021, about 9.4% of Canadian adults were readmitted within 30 days of leaving the hospital. This puts pressure on the healthcare system and costs the Canadian government around $2.3 billion each year. Current tools to predict readmissions aren’t very effective and often fail to consider marginalized groups. This problem comes from a poorly designed prediction system. We want to create a tool that can better help identify people at risk of returning to the hospital after discharge. Our research question is: How can we best predict the risk of hospital readmissions for hospitalized adults? First, we will develop a prediction framework for our new risk-prediction tool. We will do this by engaging stakeholders, including diverse patients, caregivers, and health system leaders. We will then use this framework to create a new risk-prediction tool. Then we will test the new tool against those currently in use to see how accurate it is in different settings. We are looking for participants to join group discussions and one-on-one interviews. These meetings will focus on their experiences with hospital readmissions in Alberta.

This pre-screening protocol is for people who would like to participate in a respiratory clinical trial. The protocol will allow us to determine: 1) which research project is the best fit for each person; and 2) if a person meets each study's eligibility criteria The Respiratory Clinical Trials Centre has several research projects ongoing at any time. These projects will include subjects with asthma or COPD. They can sometimes involve healthy individuals as well. If you agree to take part in the pre-screening protocol, the study team will ask you to complete three tests: 1) Spirometry 2) Methacholine Challenge 3) Allergy Skin Prick Test

Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis. It impacts approximately one in every 100 individuals. Individuals with RA experience joint pain and swelling. This can have a major impact on quality of life. If we don't treat RA , it can cause pain and disability. RA is also associated with a higher risk of heart and lung disease, and even premature death. With early and appropriate treatment, we can improve patient outcomes, including life expectancy. We are working to measure the quality of healthcare for people with RA. One of the major challenges in measuring patient outcomes is available data. In Alberta, a provincial information system called Connect Care is being implemented. This system can help us measure how we deliver care, and patient outcomes. This will support a “learning health system”. Learning health systems use healthcare data collected in day-to-day healthcare visits. We can analyze this data to generate reports. These reports help ensure that the care provided meets the highest standards. We propose to develop an Alberta Rheumatology Learning Health System. To do this, we will gather opinions from people with RA, healthcare providers and leaders. They will help us develop a set of quality measures. We will then work with data experts to track the selected quality measures over time. We will feed this information back to healthcare providers and health system leaders. We will use this information to improve healthcare delivery, and patient outcomes We will share our findings with regional and national organizations. This will help us contribute to national quality improvement efforts.